

RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE

An ultra-high-performance liquid chromatography coupled with a tandem mass spectrometry method for the quantification of edoxaban

Siriez, Romain; Evrard, Jonathan; Laloy, Julie; Dogne, Jean-Michel; Douxfils, Jonathan

Publication date:
2019

[Link to publication](#)

Citation for published version (HARVARD):

Siriez, R, Evrard, J, Laloy, J, Dogne, J-M & Douxfils, J 2019, 'An ultra-high-performance liquid chromatography coupled with a tandem mass spectrometry method for the quantification of edoxaban: The importance to measure active metabolite'.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Romain Siriez¹, Jonathan Evrard¹, Kossay Elasaad¹, Julie Laloy², Jean-Michel Dogné¹, Jonathan Douxfils^{1, 3}

¹ University of Namur, Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Namur, Belgium; ² University of Namur, Department of Pharmacy, Namur Nanosafety Center (NNC), Namur Research Institute for Life Sciences (NARILIS), Namur, Belgium; ³ Qualiblood s.a., Namur, Belgium.

Background and aim

- Although DOACs do not require regular measurements of their blood concentrations, some clinical situation may require an assessment of their concentration.
- Among the factor Xa inhibitors, edoxaban is the only compound for which some of the **metabolites** (edoxaban-M4, -M6 and -M8 (► **Figure 1**)) are reported to be pharmacologically active.
- Metabolites could potentially interfere with chromogenic assays usually used for the estimation of edoxaban concentration.
- Considering their respective **IC₅₀ towards human factor Xa**, these metabolites would inhibit factor Xa at different degree.
- In this context, we developed a **validated UHPLC-MS/MS method** to quantify simultaneously edoxaban and edoxaban-M4 in **human plasma**.




Figure 1: Postulated edoxaban metabolism for active metabolites. CES1: carboxylesterase-1; CYP3A4/5: Cytochrome P450 isoenzyme 3A4/5; IC_{50} : half-maximal inhibitory concentration; C_{max} : maximum observed plasma drug concentration

Table 1: MS/MS parameters for edoxaban, edoxaban-M4 and corresponding internal standard.

ESI+: Electrospray positive ionization mode

Compound	Ion mode	Transition type	Precursor ion (m/z)	Product ion (m/z)	Cone voltage (V)	Collision energy (eV)	Dwell time (s)
Edoxaban	ESI+	Quantification	548.212	152.169	40	32	0.035
	ESI+	Confirmation	548.212	366.19	40	20	0.035
Edoxaban-M4	ESI+	Quantification	521.162	321.176	38	24	0.035
	ESI+	Confirmation	521.162	339.12	38	18	0.035
[² H ₆]-edoxaban	ESI+	Quantification	554.316	158.160	32	30	0.035
	ESI+	Confirmation	554.316	372.27	32	18	0.035

Methods

- Electrospray ionization and chromatographic separation were optimized for the simultaneous dosage of edoxaban (3 to 500ng/mL) and edoxaban-M4 (3 to 150ng/mL) with [²H₆]-edoxaban in plasma (► **Table 1**). Ranges were chosen to cover (supra)-therapeutic ranges.
- The method was validated on a total run time of 6 minutes for calibration curves, precision, accuracy, carry-over, selectivity, matrix effect and short-time stability according to the requirements of regulatory guidelines for bioanalytical method validation provided by the EMA and the FDA.

Results and discussion : Importance of measuring pharmacologically active metabolites of edoxaban

- The method was **validated** according to the **regulatory guidelines** provided by the EMA and the FDA for the simultaneous dosage of **edoxaban (3 to 500ng/mL)** and **edoxaban-M4 (3 to 150ng/mL)** with [²H₆]-edoxaban in plasma (► **Figure 2**).
- A potential interest of synchronously measuring edoxaban and edoxaban-M4 is to obtain complementary information about the **impact of the active metabolite in chronometric or chromogenic assays**. This is especially important since at **low concentration (<30ng/mL)** a **deviation of more than 50% has been observed (anti-Xa vs LC-MS/MS)**, suggesting that **anti-Xa assays are not able to provide reliable results** in these low values.
- **Limitation** : Edoxaban-M6 was not investigated. Regarding its IC_{50} (6.9nM) and C_{max} (8.55ng/mL), the impact on chromogenic assays should be negligible contrary to the impact of the edoxaban-M4 which has a lower IC_{50} (1.8nM) and a higher C_{max} (23.1ng/mL) (► **Figure 1**).
- In addition, this technique could be interesting in case of **drug-drug interactions** which are frequently reported (e.g. co-treatment with *quinidine*, *verapamil*, *ketoconazole*, *rifampin*, *cyclosporine*, *erythromycin*, ...). These interactions disturbed the parent-to-metabolite ratio explaining for ther the imprecision of standard chromogenic methods.




Figure 2: Calibration curves for measurement of edoxaban and edoxaban-M4 in plasma with UHPLC-MS/MS in presence of ²H₆-edoxaban (internal standard). The blue and orange lines represent the calibration lines of the edoxaban (3 to 500ng/mL) and edoxaban-M4 (3 to 150ng/mL), respectively.

Conclusion

- This method permits quantification of **edoxaban and edoxaban-M4** providing complementary information about the inhibitory effect of this active metabolite in chronometric or chromogenic assays.
- Although patients treated with edoxaban exhibits usually low concentrations of active metabolites, the measurement of edoxaban-M4 is interesting; especially in case of **drug interactions**. Indeed, concomitant prescriptions of edoxaban and *carbamazepine* or *rifampicin* is frequent and may lead to disturbance of the estimations of edoxaban concentration by chromogenic anti-Xa assays.
- Therefore, patients are at risk of having **inadequate control of anticoagulation** supporting the need of measuring the most representative edoxaban metabolite concomitantly to the parent compound.